Search results
Jump to navigation
Jump to search
- [[Category:Neuropathology tumours]] [[Category:WHO grade II tumours]]158 bytes (15 words) - 15:19, 15 October 2015
- *Oligoastrocytoma, NOS (Grade II WHO; ICD-O: 9382/3) *Anaplastic Oligoastrocytoma, NOS (Grade III WHO; ICD-O: 9382/3)2 KB (277 words) - 10:38, 20 May 2016
- | Site = all ventricles, [[cerebellopontine angle]] - see ''[[brain tumours]]'' *Low grade4 KB (475 words) - 02:19, 7 July 2015
- | Site = [[brain]] - see ''[[neuropathology tumours]]'' | Prognosis = WHO grade I5 KB (596 words) - 14:00, 8 July 2020
- '''Diffuse astrocytoma''' (AKA: ''diffuse, low-grade astrocytoma'') is a infiltrating astrocytoma occurring in the CNS white mat * Most common grade II WHO glioma in adults (peaks between 30-40 years).8 KB (1,059 words) - 08:12, 27 May 2019
- The current WHO classification recognizes three tumour grades: * Astrocytoma, IDH mutant grade 2 (ICD-O: 9400/3)11 KB (1,346 words) - 09:10, 14 April 2022
- ...use astrocytomas. An overview of other CNS tumours is found in the ''[[CNS tumours]]'' article. * Common vs. uncommon tumours.13 KB (1,555 words) - 13:48, 17 October 2022
- *Currently no WHO grade assigned.<ref>{{Cite journal | last1 = Louis | first1 = DN. | last2 = Perr ** From 2007-2016 the tumor was ''WHO Grade II'' by definition.<ref name=Ref_PSNP86>{{Ref PSNP|86}}</ref> Grading was drop4 KB (502 words) - 13:49, 18 May 2016
- '''Anaplastic astrocytoma''' (AKA: ''high-grade astrocytoma'') is a infiltrating neoplasm of the diffuse astrocytic and oli * Most common grade III WHO glioma in adults (peaks between 40-50 years).7 KB (840 words) - 09:24, 19 March 2018
- {{hidden|Diagnosis|<center>PILOMYXOID ASTROCYTOMA GRADE II WHO WITH KIAA1549(Exon15)-BRAF(Exon9) FUSION</center> ...| title = Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma6 KB (717 words) - 02:38, 27 September 2015
- ...= [[soft tissue lesions|soft tissue]] - [[fibroblastic/myofibroblastic tumours]], pleura ...esion|soft tissue tumour]] that fits in the [[fibroblastic/myofibroblastic tumours]]. It is usually benign.8 KB (955 words) - 07:21, 15 December 2016
- *Moderately aggressive (WHO Grade II).<ref name=pmid11465399>{{Cite journal | last1 = Fouladi | first1 = M. | l *Anaplastic PXA (grade III) - rare. <ref>{{Cite journal | last1 = Louis | first1 = DN. | last2 =7 KB (920 words) - 12:38, 11 October 2019
- Tumours:<ref name=pmid20971711>{{cite journal |author=Gaillard F, Jones J |title=Ma *Primary pineal tumours ~15% of (pineal) tumours - benign to malignant:<ref name=pmid21057132>{{cite journal |author=Smith A12 KB (1,634 words) - 17:20, 25 March 2021
- | Caption = Ependymoma grade II WHO. [[H&E stain]] | Prognosis = intermediate to poor (WHO Grades II & III)18 KB (2,184 words) - 13:20, 19 September 2022
- ...related to [[pilocytic astrocytoma]]. The future WHO classification of CNS tumours will include it as separate entity. ...ade assigned. Molecular class MC-1 corresponds to WHO I, class MC-2 to WHO II/III<ref name="pmid29766299">{{cite journal |authors=Deng MY, Sill M, Chiang9 KB (1,148 words) - 17:20, 25 March 2021
- | Site = [[neuropathology tumours]] - cerebral hemispheres, posterior fossa (rare), spinal cord (very rare) | Prognosis = moderate - dependent on grade16 KB (1,953 words) - 09:32, 6 April 2022
- This article covers '''fibroblastic/myofibroblastic tumours'''. These tumours fit into the larger category of [[soft tissue lesions]]. =List of tumours=20 KB (2,365 words) - 18:58, 24 March 2019
- | Site = [[kidney]] - see ''[[kidney tumours]]'' | ClinDDx = other [[kidney tumours]]13 KB (1,734 words) - 20:08, 20 December 2019
- ...Tumours are a large part of [[neuropathology]]. [[Cytopathology]] of CNS tumours is dealt with in the article ''[[CNS cytopathology]]''. There are separate articles for ''[[peripheral nerve sheath tumours]]'' and ''[[pituitary gland|pituitary/peri-pituitary lesions]]''.33 KB (3,993 words) - 09:04, 14 April 2022
- ...skochil DH |title=Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in spo *grade IV: Presence of necrosis (3/4 of all MPNST).12 KB (1,493 words) - 09:28, 27 April 2017